A 65-year-old man was found to have a mass lesion surrounded by ground-glass attenuation in the left upper lobe on chest radiography. He was diagnosed with stage IA adenocarcinoma of the lung. The resected lung specimen revealed papillary adenocarcinoma associated with infiltralion of numerous lymphocytes in the alveolar septa, which was consistent with focal lymphocytic interstitial pneumonia (LIP). However, it was not associated with Sjögren's syndrome or any other immunologic abnormalities. Immunohistochemical study disclosed that CD8 positive T-cells constituted the major element of the infiltrated lymphocytes in the tumor, and were also found in the enlarged alveolar septa, suggesting an association between lung cancer and LIP. To our knowledge, this is the first description of an association between LIP and lung cancer. In addition, the focal LIP in this case probably reflected local immune response to an antigenic stimulus caused by lung cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2169/internalmedicine.41.997 | DOI Listing |
Adv Sci (Weinh)
January 2025
Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
In triple-negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, a previously identified CD206 (mannose receptor)-binding peptide, mUNO was engineered to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I.
View Article and Find Full Text PDFThorac Cancer
January 2025
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Tracheal, bronchial, and lung cancers (TBL cancers) pose a significant global health challenge, with rising incidence and mortality rates, particularly in China. Studies from the Global Burden of Disease (GBD), 2021, can guide screening and prevention strategies for TBL cancer. This study aims to provide a comprehensive analysis of the burden of TBL cancers in China compared to global data.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
The department of oncology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Non-small cell lung cancer (NSCLC) frequently metastasizes to the brain, significantly worsened prognoses. This study aimed to develop an interpretable model for predicting survival in NSCLC patients with brain metastases (BM) integrating radiomic features and RNA sequencing data. 292 samples are collected and analyzed utilizing T1/T2 MRIs.
View Article and Find Full Text PDFCureus
December 2024
Department of Cancer Biochemistry and Radiobiology, Institutul Oncologic Prof. Dr. Alexandru Trestioreanu, Bucharest, ROU.
Malignant pleural effusion (MPE) is a common feature in patients with advanced or metastatic malignancies. While significant progress has been made in understanding the biology of pleural effusions, further research is needed to uncover the subsequent behavior of tumor cells following their invasion into the pleural space. This report utilizes flow cytometry to analyze DNA content abnormalities (aneuploidy) and cell cycle status, shedding light on the tumor cell populations present in MPE samples from a patient with lung adenocarcinoma during treatment.
View Article and Find Full Text PDFCureus
December 2024
Pathology and Laboratory Medicine, Arrowhead Regional Medical Center, Colton, USA.
Thoracic SMARCA4-deficient undifferentiated tumor (TSDUT) is a rare and quite new classification of primary pulmonary malignancy. It is classified as a non-small cell lung cancer, typically associated with smoking, and is highly aggressive. Its clinical features, immunohistochemistry, and pathology are quite unique.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!